

## 5 LITERATURVERZEICHNIS

Albert M L, Sauter B und Bhardwaj N, 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature*, 392: 86-89

Altmann JD, Moss PA, Goulder PF, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ und Davis MM, 1996. Phenotypic analysis of antigen-specific T lymphocytes. *Science*, 274: 94-96

Andersson U, Hallden G, Persson U, Hed J, Moller G und DeLey M, 1988. Enumeration of IFN $\gamma$ -producing cells by flow cytometry. Comparison with fluorescence microscopy. *J Immunol Methods*, 112:139-142

Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V und Parmiani G, 1999. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from Immune surveillance in metastatic lesions. *J Exp Med*, 190:651-668

Appay V und Rowland-Jones S, 2002 (b). The assessment of antigen-specific CD8<sup>+</sup> T cells through the combination of MHC class I tetramer and intracellular staining, *J Immunol. Methods* 268: 9-19.

Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael A und Rowland-Jones SL, 2002 (a). Memory CD8<sup>+</sup> T cells vary in differentiation phenotype in different persistent virus infections. *Nature Med*, 8: 379-385.

- Appleman LJ, Boussiotis VA, 2003. T cell energy and costimulation. *Immunol Rev*, 192:161-80.
- Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J und Hamilton JM, 2000. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. *Cancer Immunol Immunother*, 49(10):517-29.
- Arosarena OA, Baranwal S, Strome S, Wolf GT, Krauss JC, Bradford CR und Carey TE, 1999. Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer. *Otolaryngol Head Neck Surg*;120:665-71.
- Asai T, Storkus WJ und Whiteside TL, 2000. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. *Clin Diagn Lab Immunol*, 7:145-54.
- Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Schmittel A, Thiel E und Scheibenbogen C, 2001. Flow cytometric determination of intracellular or secreted IFN $\gamma$  for the quantification of antigen reactive T cells. *J Immunol Methods*, 251:101-8.
- Assenmacher M, Löhning M, Scheffold A, Manz RA, Schmitz J und Radbruch A, 1998. Sequential production of IL-2, IFN- $\gamma$  and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes. *Eur J Immunol*, 28:1534-1543.
- Assenmacher M, Scheffold A, Schmitz J, Segura Checa JA, Miltenyi S und Radbruch A, 1996. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. *Eur J Immunol*, 26: 263-267.
- Atkins MB, Robertson M, Gordon MS, Lotze MT, Du Bois J, Ritz J, Sandler A, Edington HD, and Sherman ML, 1996. Phase I evaluation of intravenous recombinant human IL-12 in patients with advanced malignancies. *Proceedings of ASCO. Journal of Clinical Oncology*, 15, Abstract No. 718.

- Aulitzky W, Gastl G, Aulitzky WE, Nachbaur K, Lanske B, Kemmler G, Flener R, Frick J, Huber C, 1987. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. *Immunobiology*, 176:85-95.
- Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Stienman R und Fay J, 2001. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. *Cancer Res*, 61:6451-6458.
- Barao I und Ascensao JL, 1998. Human natural killer cells. *Arch Immunol Ther Exp*, 45:213-229.
- Becker C, Pohla H, Frankenberger B, Schüler T, Assenmacher M, Schendel D J und Blankenstein T, 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN $\gamma$  capture assay. *Nature med*, 7:1159-1162.
- Bednarek MA., Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR und Zweerink H, 1991. The minimum peptide epitope from the influenza matrix protein. *J Immunol*, 147:4047-4053.
- Bell EB und Sparshott SM, 1990. Interconversion of CD45R subsets of CD4 T cells in vivo. *Nature*, 348: 163-165.
- Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM und Stauss HJ, 2002. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. *Blood*;100:3835-3857.
- Belldegrun A, Muul LM und Rosenberg SA, 1988. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation characterization and antitumor activity. *Cancer Res*, 49:206-214.
- Boon T and Old LJ, 1997. Cancer Tumor antigens. *Curr Opin Immunol*, 9:681-683.

- Boon T, De Plaen E, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C, Amar-Costesec A und Van Pel A, 1992. Identification of tumour rejection antigens recognized by T lymphocytes. *Cancer Surv*, 13:32-37.
- Borrego F, Kabat J, Dae-Ki K, Lieto L, Maasho K, Pena J, Solana R und Coligan JE, 2001. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. *Mol Immunol*, 38:637-660.
- Boshoff C und Weiss R, 2002. AIDS-related malignancies. *Nature Rev Cancer*, 2:373-382.
- Bromberg JF, Horvath CM, Wen Z, Schreiber RD und Darnell JE Jr, 1996. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. *Proc Natl Acad Sci USA*, 93:7673-7678
- Brosterhus H, Brings S, Leyendeckers H, Manz RA, Miltnyi S, Radbruch A, Assenmacher M und Schmitz J, 1999. Enrichment and detection of live antigen-specific CD4+ and CD8+ T cells based on cytokine secretion. *Eur J Immunol*. 29,4053-4059.
- Brunner KT, Mael J, Cerottini JC und Chapuis B, 1968. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. *Immunology*, 14:181-196.
- Burnet F M, 1970. The concept of immunological surveillance. *Progress in Experimental Tumor Research* 13:1-27.
- Burnet FM, 1957. Cancer –a biological approach. *BMJ*, 1:841-847.
- Cabrera T ,Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A und Garrido F, 1996. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. *Hum Immunol*, 50:127-134.

- Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB, 1998. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. *J Exp Med*, 187:1395-1402.
- Campbell JJ, Murphy KE, Kunkel EJ, Brighting CE, Soler D, Shen Z, Boisvert J, Greenberg HB, Vierra MA Goodman SB, Genovese MC, Wardlaw AJ, Butcher EC und Wu L, 2001. CCR7 expression and memory T cell diversity in humans. *J Immunol*, 166:877-884.
- Chaux P, Moutet M, Faivre J, Martin F und Martin M, 1996. Inflammatory cells infiltration human colorectal carcinomas express HLA class II but not B7.1 and B7.2 costimulatory molecules of the T cell activation. *Lab Invest*, 74:975-983.
- Cohen Y, Solal-Celigny P und Polliack A, 2003. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. *Haematologica*.88:811-23.
- Coley WB, 1893. A Preliminary Note on the Treatment of Inoperable Sarcoma by the Toxic Product of Erysipelas. *Post-graduate* 8:278-86.
- Cormier JN , Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM und Topalian SL, 1998. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A and gp 100 in metastatic melanoma lesions. Implications for immunotherapy. *J Immunother*, 21:27-31.
- Coulie P G, Ikeda H, Baurain J-F und Chiari R, 1999. Antitumor immunity at work in a melanoma patient. *Adv Cancer Res*. 76:213-42.
- Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al, 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med*, 180:35-42.

- Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ und Walboomers JM, 1994. Loss of transporter protein, encoded by the Tap-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. *J Exp Med*, 179:335-340.
- Czerkinsky CC, Anderson G und Ekre HP, 1988. Reverse ELISPOT assay for clonal analysis of cytokine production. Enumeration of gamma-interferon secreting cells. *J Immunol Methods*, 110:29-36.
- Czerkinsky CC, Nielsson LA, Nygren H, Ouchterlony O und Tarkowske A, 1983. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. *J Immunol Methods*, 65:109-121
- Darrow TL, Abdel-Wahab Z, Quinn-Allen MA und Seigler HF, 1996. Recognition and lysis of human melanoma by a CD3+CD4+, CD8- T-cell clone restricted by HLA-A2. *Cell Immunol*, 172:52-59.
- De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, Sibille C, Chomez P und Boon T, 1988. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. *Proc Natl Acad Sci USA*, 85:2274-2278.
- Dhodapkar M V, Young J W, Chapman P B, Cox W I, Fonteneau J F, Amigorena S, Houghton AN, Steinman R M und Bhardwaj N, 2000. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma Patients. *Clin Cancer Res*, 6:4831-4838.
- Dobrzanski MJ, Reome JB und Dutton RW, 2000. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. *J Immunol*, 164:916-925.

- Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE und Rosenberg SA, 2002. Cancer Regression and autoimmunity in Patients after clonal repopulation with antitumor lymphocytes. *Science*, 298: 850-854.
- Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P and Cerundolo V, 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. *Curr Biol*, 8:413-416.
- EIGhazali GE, Paulie S Andersson G , Hansson Y, Holmquist G, Sun JB, Olsson T, Ekre HP, Troye-Blomberg M. 1993. Number of interleukin-4 and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. *Eur J Immunol*; 23:2740-2745.
- Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW und Street NE, 1999. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. *J Immunol*, 162:2842-2849.
- Fong L, Hou Y, Rivas A, Benike C, Quen A, Fisher GA, Davis MM und Engleman EG, 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. *Proc Natl Acad Sci U S A*, 98:8809-8814.
- Gamadia, LE, Rentenaar RJ, Temmerswaal EB M, Surachno S, Weel JFL, Toebes M, Schumacher TNM, van Lier RAW und ten Berge IJM, 2001. CMV-specific CD8+ T lymphocyte differentiation in latent CMV infection. *Transplant Proc*, 33, 1802-1803.
- Garcia-Lora A, Algarra I und Garrido F, 2003. MHC class I antigens, immune surveillance, and tumor immune escape. *J Cell Physiol*, 195:346-355.

- Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C und Nadler LM, 1991. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. *Proc Natl Acad Sci USA*, 88:6575-6579.
- Greten TF und Jaffee EM, 1999. Cancer vaccines. *J Clin Oncol*, 17:1047-1060.
- Griffioen M, Borghi M, Schrier PI and Osanto S, 2001. Detection and quantification of CD8(+) T cells specific for HLA-A\*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. *Int J Cancer*, 93:549-555.
- Hamann D, Baars P A, Rep M H, Hooibrink B, Kerkhof-Garde S R, Klein M R und van Lier, 1997. Phenotypic and functional separation of memory and effector human CD8+ cells. *J Exp Med*, 186:1407-1418.
- Hamann D, Kostense S, Wolters K C, Otto S A, Baars P A, Miedema F und van Lier R A, 1999. Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. *Int Immunol*, 11:1027-1033
- Heemels MT und Ploegh H, 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. *Annu Rev Biochem*, 64:463-491.
- Herr W, Schneider J, Lohse AW, Meyer zum Büschenfelde KH und Wölfel T, 1996. Detection and quantification of blood-derived CD8+ T lymphocytes secreting TNF $\alpha$  in response to HLA-A2.1 binding melanoma and viral antigens. *J Immunol Methods*, 191, 131-142.
- Höflich C, Docke WD, Busch A, Kern F, Volk HD, 1998. CD45RA(bright)/CD11a(bright) CD8+ T cells: effector T cells. *Int Immunol*, 10:1837-1845.
- Hom SS, Schwartzentruber DJ, Rosenberg SA und Topalian SL, 1993. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. *J Immunother*, 13:18-30.



- Hsieh WS, Lemas MV und Ambinder RF, 1999. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. *Transpl Infect Dis*, 1:204-212.
- Hu J, Kindsvogel W, Busby S, Bailey MC, Shi YY und Greenberg PD, 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. *J Exp Med*, 177:1681-1690.
- Itoh K, Platsoucas CD und Balch CM, 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. *J Exp Med*, 68:1419-1441.
- Jacob L, Somasundaram R, Smith W, Monos D, Basak S, Marincola F, Pereira S und Herlyn D, 1997. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. *Int J Cancer*, 71: 325-332.
- Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Darbach J, Dunbar PR, Lee SY, Jungbluth A, Fäger D, Arand M, Ritter G, Cerundulo V, Dupont B, Chen YYT, Old LJ und Knuth A, 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. *Proc Natl Acad Sci USA*, 97: 4760-4765.
- Jenne L, Arrighi JF, Jonuleit H, Saurat JH und Hauser C, 2000. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. *Cancer Res*. 60:4446-4452.
- Jung T, Schauer U; Heusser C, Neumann C und Rieger C, 1993. Detection of intracellular cytokines by flow cytometry. *J Immunol Methods*, 159:197-207.
- Kaech S M, Wherry E J und Ahmed R, 2002. Effector and memory T-cell differentiation: implications for vaccine development. *Nature Immunol Rev*. 2:251-262.

- Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ und Schreiber RD, 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. *Proc Natl Acad Sci USA* , 95:7556-61
- Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T und Coulie PG, 2001. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with long survival. *Cancer Res*, 61:3718-3724.
- Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR und Rosenberg SA, 2000. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. *J Immunother*, 23:17-27.
- Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E und Rosenberg SA, 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. *J Immunol*, 154:3961-3968.
- Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E und Rosenberg SA, 1998. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. *J Immunol*. 161:6985-6992.
- Keilholz U und Eggermont AM, 2000. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. *Cancer J Sci Am*, 6 Suppl 1:S99-103.
- Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F und Eggermont AM, 1997. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. *Cancer J Sci Am*, 3 Suppl 1:S22-28.

- Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lysterly HK, Lee PP, Storkus W, Marincola F, Worobec A und Atkins MB, 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. *Journal of Immunotherapy*, 25:97-138.
- Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P und Volk HD, 1998. T-cell epitope mapping by flow cytometry. *Nature Med*, 4:975-988.
- Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM und Ithoh K, 1994. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. *Int J Cancer*. 58:317-323.
- Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr und Shabanowitz JA, 1998. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. *J Immunol*, 160:2099-2106.
- Kontani K, Taguchi O, Narita T, Izawa M, Hiraiwa N, Zenita K, Tekuchi T, Murai H, Miura S und Kannagi R, 2001. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. *Br J Cancer*, 84: 1258-1264.
- Koopman LA, Corver WE, van der Silk AR, Giphart MJ und Fleuren GJ, 2000. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. *J Exp Med*, 191:961-975.
- Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL and Gatter KC, 1996. Loss of antigen-presenting molecules (MHC class I and TAP 1) in lung cancer. *Br J Cancer*, 73: 148-153.

- Koyama S, Maruyama T, Adachi S und Nozue M, 1998. Expression of costimulatory molecules, B7.1 and B7.2 on human gastric carcinoma. *Journal of Cancer Research and Clinical Oncology*, 124: 383-388.
- Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV und McMichael, AJ, 1997. Rapid effector function in CD8<sup>+</sup> memory T cells. *J Exp Med*, 186:859-865.
- Lanier LL, 1998. NK cell receptors. *Annu Rev Immunol*. 16: 359-393.
- Lanzavecchia A, 1998 (a). Immunology. Licence to kill. *Nature*. 393:413-414.
- Lanzavecchia A, 1998 (b). From antigen presentation to T-cell activation. *Res Immunol*, 149:626.
- Lanzavecchia A, Lezzi G und Viola A, 1999. From TCR engagement to T cell activation: a kinetic view of T cell behavior. *Cell*, 96:1-4.
- Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M und Davis MM, 1999. Characterization of circulation T cells specific for tumor-associated antigens in melanoma patients. *Nature Med*, 5:677-685.
- Legha SS, 1986. Interferons in the treatment of malignant melanoma. A review of recent trials. *Cancer*. 57:1675-7.
- Lehner PJ und Cresswell P, 1996. Processing and delivery of peptides presented by MHC class I molecules. *Curr Opin Immunol*. 8:59-67.
- Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E und Scheibenbogen, C., 2000. High frequencies of circulating melanoma-reactive CD8<sup>+</sup> T cells in patients with advanced melanoma. *Int J Cancer*, 87:659-664.
- Levine AM, 1994. Lymphoma complicating immunodeficiency disorders. *Ann Oncol*, 5:29-35

- Lindelof B, Sigurgeirsson B, Gabel H und Stern RS, 2000. Incidence of skin cancer in 5356 patients following organ transplantation. *Br J Dermatol*, 143: 513-519.
- Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R und Bartolucci AA, 1991. *Corynebacterium parvum* versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. *J Clin Oncol*, 9:1151-1156
- Lotze MT, Zeh HJ 3rd, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL und Herberman R, 1992. Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. *J Immunother*. 12:212-217.
- Ludwig G, Jentzsch R und Nuri M, 1977. Spontanremissionen von Lungenmetastasen beim Hypernephrom: Fallbeschreibung und Literaturübersicht. *Medizinische Klinik*, 72:2118-2121
- Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J und Boon T, 1989. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. *Cell*. 58:293-303.
- Maher S, Toomey D, Condron C und Bouchier-Hayes D, 2002. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. *Immunol Cell Biol*, 80:131-137.
- Maino VC und Picker LJ, 1998. Identification of Functional Subsets by Flow Cytometry: Intracellular Detection of Cytokine Expression. *Cytometry (Communications in Clinical Cytometry)* 34:207-215
- Manz R, Assenmacher M, Pflüger E, Miltenyi S und Radbruch A, 1995. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. *Proc Natl Acad Sci USA*, 92:1921-1925.

- Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T und Stoter G, 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. *Eur J Cancer*. 39:70-77
- Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P und Boon T, 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer*, 80:219-230.
- Marincola FM, White DE, Wise AP und Rosenberg SA, 1995. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. *J Clin Oncol*, 13:1110-1122.
- Mathé G, Amiel JL, Schwarzenber L, Catatan A und Schneider M, 1965. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. *Cancer Res*, 25, 1525-1531.
- Matzinger P, Guerder S, 1989. Does T cell tolerance require a dedicated antigen-presenting cell? *Nature*, 338: 74-76.
- Medhat A, Shehata M, Bucci K, Mohamed S, Dief AD, Badary S, Galal H, Nafeh, M und King CL, 1998. Increased interleukin-4 and interleukin-5 production on response to *Schistosoma haematobium* adult worm antigens correlates with lack of reinfection after treatment. *J Infect Disl*, 178:512-519.
- Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen und Mackensen A, 2003. Survival and tumor localization of adoptively transferred melanA-specific T cells in melanoma patients. *J Immunol*, 170: 2161-2169.

- Merville P, Pouteil-Noble C, Wijdenes J, Potaux :, Touraine JL und Bachereau J, 1993. Detection of single cells secreting IFN-gamma, IL-6 and IL-10 in irreversible rejected human kidney allografts, and their modulation by IL-2 and IL-4. *Transplantation*, 55:639-646.
- Mischo A, Wadle A, Watzig K, Jager D, Stockert E, Santiago D, Ritter G, Regitz E, Jager E, Knuth A, Old L, Pfreundschuh M und Renner C, 2003. Recombinant antigen expression on yeast surface (RAYs) for the detection of serological immune responses in cancer patients. *Cancer Immunity*. 27;3:5.
- Mitchell M S, Darrah D, Yeung D, Hlapern S, Wallace A, Volland J, Jones V und Kan-Mitchell J, 2002. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. *J Clin Oncol*, 20:1075-1086.
- Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM und Zavala F, 1995. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. *J Immunol Methods*, 181:45-54.
- Moingeon P, 2001. Cancer Vaccines. *Vaccine*, 19:1305-1326
- Moldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE und Davis MM, 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. *Nature Med*, 6:1018-1023.
- Morales A, Eidinger D und Bruce AW, 1976. Intracavitary Bacillus Calmette Guérin in the treatment of superficial bladder tumors. *J Urol*, 116:18-21.
- Moretta L, Ferlazzo G, Mingari MC, Melioli G und Moretta A, 2003. Human natural killer cell function and their interactions with dendritic cells. *Vaccine*, 21 Suppl 2:S38-42.
- Moretta L, Mingari M C Pende D, Bottino C, Biassoni R und Moretta A, 1996. The molecular basis of natural killer (NK) cell recognition and function. *J Clin Immunol*, 16: 243-253.

- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA und Coffman RL, 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol*, 136:2348-2357.
- Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT, 1989. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. *J Exp Med*. 169:1961-1976.
- Müller L, Kiessling R, Rees R C und Pawelec G, 2002. Escape Mechanisms in Tumor Immunity: An Update. *J Environ Pathol Toxicol Oncol*, 21: 277-330.
- Nagorsen D, Keilholz U, Rivoltini L, Letsch A, Asemisen AM, Thiel E und Scheibenbogen C, 2000. Natural T cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. *Cancer Res*, 50:4850-4854.
- Nestle FO, Aljagic S, Gilliet M Nestle FO, Aljagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G und Schadendorf D, 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nature Med*, 4:328-332.
- Nielsen MB und Marincola FM, 2000. Melanoma vaccines: the paradox of T cell activation without clinical response. *Cancer Chemother Pharmacol*, 46, Suppl: S62-66.
- Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ und Rosenberg SA, 1999. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. *Cancer Res*, 59:6230-8.
- Nordstrom I und Ferrua B, 1992. Reverse ELISPOT assay for clonal analysis of cytokine production. II. Enumeration of interleukin-1-secreting cells amplified (avidin-biotin anti-peroxidase) assay. *J Immunol Methods*, 150:199-206.



- Oelke M, Moehrle U, Chen J-L, Behringer D, Cerundolo V, Lindemann A und Mackensen A, 2000. Generation and Purification of CD8+ Melan-A-specific Cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. *Clin Cancer Res*, 6:1997-2005.
- Ogg GS, Cunbar RP, Romero P, Chen JL und Cerundolo V, 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. *J Exp Med*, 188:1203-1208.
- Ohnmacht G A and Maricola F, 2000. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. *J Cell Physiol*, 182:332-338.
- Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K und Sugiyama H, 2000. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. *Immunogenetics*, 51:99-107.
- Österborg A, Yi Q, Hendriksson L et al., 1998. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced typ I, major histocompatibility complex-restricted, CD8+ and CD4- specific T-cell responses. *Blood*, 91:2159-2466.
- Parkhurst MR, DePan C, Riley JP, Rosenberg SA und Shu S, 2003. Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules. *J Immunol*, 170:5317-5325.
- Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA und Kawakami Y, 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A\*0201-binding residues. *J Immunol*, 157:2539-2548.

- Pass HA, Schwarz SL, Wunderlich JR und Rosenberg SA, 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. *Cancer J Sci Am*, 4:316-23.
- Pittet J P, Zippelius A, Speiser D E, Assenmacher M, Guillaume P, Valmori D, Liénard D, Lejeune F, Cerottini J-C und Romero P, 2001. Ex vivo IFN- $\gamma$  secretion by circulation CD8 T lymphocytes: Implication of a novel approach for T cell monitoring in infectious and malignant diseases. *J Immunol*, 166:7634-7640.
- Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC und Romero P, 1999. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. *J Exp Med*, 190:705-715.
- Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC und Romero P, 2002. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. *Trends Immunol*, 23:325-328.
- Prussin C und Metcalfe DD, 1995. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. *J Immunol Methods*, 188:117-128.
- Prussin C, 1997. Cytokine flow cytometry: understanding cytokine biology at the single-cell level. *J Clin Immunol*, 17:195-204.
- Rammensee H, Bachmann J, Emmerich NP, Bachor OA und Stevanovic S, 1999. SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics*, 50:213-219.
- Rammensee HG, 1996. Antigen presentation - recent developments. *Int Arch Allergy Immunol*, 110:299-307.
- Redman BG, Flaherty L, Chou TH, Kraut M, Martino S, Simon M, Valdivieso M und Groves E, 1992. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. *J Immunother*, 12:50-54.

- Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P, Janssen H, Calafat J, Drijfhout JW und Neefjes J. 2003. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. *Immunity*. 18:97-108.
- Renkvist N, Castelli C, Robbins PF und Parmiani G, 2001. A listing of human tumor antigens recognized by T cells. *Cancer Immunol Immunother*, 50:3-15.
- Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M und Bystryn JC, 2000. Identification of HLA-A\*03, A\*11 and B\*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. *J Immunol Methods*, 244:59-67.
- Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S and Marincola FM, 1999. Immune selection after antigen-specific immunotherapy of melanoma. *Surgery*, 126:112-120.
- Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P und Valmori D, 2000. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. *J Immunol*, 165:7253-7261.
- Romero P, Cerottini JC und Waanders GA, 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. *Mol Med Today* 4, 305-312.
- Rininsland FH, Helms T, Asaad RJ, Boehm BO und Tary-Lehmann M, 2000. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. *J Immunol Methods*. 240:143-55.

- Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC und Cerundolo, V. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. *J Exp Med*, 188:1641-1650.
- Romero P, Pittet M, Dutoit V, Zippelius A, Liénard D, Lejeune F, Guillaume P, Rimoldi D, Vamori D, Speiser DE und Cerottini J-C, 2002. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. *Vaccine* 20: A2-A7.
- Rosenberg SA, 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. *Immunol Today*, 18:175-182.
- Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al, 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med*, 316:889-897.
- Rosenberg SA, Qiang JC, Scharzentruher DJ, Hwu P, Marincola FM, Tobalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Ogers-Freezer L und White DE, 1999 (b). Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. *J Immunol*, 163:1690-1695.
- Rosenberg SA, Spiess P und Lafreniere R, 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. *Science*.233:1318-1321.
- Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH und White DE, 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. *J Natl Cancer Inst*, 86:1159-1166.

- Sahin U, Tureci O und Pfreundschuh M, 1997. Serological identification of human tumor antigens. *Curr Opin Immunol*, 9:709-716.
- Sallusto F, Lenig D, Forster R, Lipp M und Lanzavecchia A, 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*, 401:708-712.
- Sandberg JK, Fast NM und Nixon DF, 2001. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8(+) T lymphocytes. *J Immunol*. 167:181-187
- Sawicki MW, Dimasi N, Natarajan K, Wang J, Margulies DH und Mariuzza RA, 2001. Structural basis of MHC class I recognition by natural killer cell receptors. *Immunol Rev*, 181:52-65.
- Scheffold A, Assenmacher M, Reiners-Schramm L, Lauster R und Radbruch A, 2000. High-sensitivity immunofluorescence for detection of the pro-and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells. *Nature med*, 6:107-110.
- Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee H-G und Keilholz U, 1997 (a). A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. *Clin Cancer Res*. 3, 221-226.
- Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naehrer H, Rammensee HG und Keilholz U, 1997 (b). Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. *Int J Cancer*, 71:932-936.
- Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E und Schadendorf D, 2000 (a). Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. *J Immunother*, 23:275-281.

- Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A., Cerottini JC, Woelfel T, Eggermont AMM und Keilholz U, 2000 (b). Quantitation of antigen-reactive T cells in peripheral blood by interferon-gamma ELISPOT-assay and chromium-release assay: a four-centre comparative trial. *J Immunol Methods*, 244, 81-89
- Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG und Schadendorf D, 2002 (a). Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. *Int J Cancer*, 98:409-414.
- Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E und Keilholz U, 2002 (b). Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. *Int J Cancer*, 99:403-408.
- Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D und Keilholz U, 2002 (c). CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. *Blood*, 100:2132-2137.
- Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E und Keilholz U, 2003. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. *Int J Cancer*. 104:188-194.
- Schmid DS, Thieme ML, Gary HE Jr und Reeves WC, 1997. Characterization of T cell response to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISPOT cytokine assay. *Arch Virol*, 142:1659-1671.
- Schmittel A, Keilholz U und Scheibenbogen C, 1997. Evaluation of the interferon-gamma ELISPOT-assay of peptide specific T lymphocytes from peripheral blood. *J Immunol Methods*, 210, 167-174.

- Schmittel A, Keilholz U, Thiel E und Scheibenbogen C, 2000. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. *J Immunother*, 23:289-295.
- Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampe R und Huber C, 1997. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. *Exp Hematol*, 25:608-614.
- Seliger B, Dunn T, Schwenzler A, Casper J, Huber C und Schmoll HJ, 1997. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma. *Scand J Immunol*, 46:625-32.
- Sharpe AH und Freeman GJ, 2002. The B7-CD28 superfamily. *Nat Rev Immunol*, 2:116-26.
- Sijts A, Zaiss D und Kloetzel PM, 2001. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. *Curr Mol Med*, 1:665-676.
- Sinkovics JG, 1991. Viral oncolysates as human tumor vaccines. *Int Rev Immunol*;7(4):259-87.
- Smyth MJ und Trapani JA, 1995. Granzymes: exogenous proteinases that induce target cell apoptosis. *Immunol Today*, 16:202-206.
- Starzl TE, Porter KA, Iwatsuki S, Rosenthal JT, Shaw BW und Atchinson RW, 1990. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. *Lancet*, 1:583-587
- Strasser A, O'Connor L und Dixit VM, 2000. Apoptosis Signaling. *Annu Rev Biochem*, 69:217-245.
- Sun H, Kundu N, Dorsey R, Jackson MJ und Fulton AM, 2001. Expression of the Chemokines IP-10 and Mig in IL-10 Transduced Tumors. *J Immunother*, 24:138-143.

- Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T, Carcelain G und Autran B, 2003. A systematic comparison of methods to measure HIV-q specific CD8 T cells. *J Immunol Methods*, 272:23-34.
- Sun Y, Paschen A und Schadendorf D, 1999. Cell-based vaccination against melanoma-background, preliminary results, and perspective. *J Mol Med*, 77:593-608.
- Suni MA, Picker LJ und Maino VC, 1998. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. *J Immunol Methods*, 212, 89-98.
- Suri D, Schilling R, Lopes AR, Mullerova I, Colucci G, Williams R und Naoumov NV, 2001. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. *J Hepatol*, 35:790-797.
- Taswell C, 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. *J Immunol*, 126:1614-1619.
- Topalian SL, Muul LM, Solomon D und Rosenberg SA, 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. *J Immunol Methods*, 102:127-141.
- Topalian SL, Solomon D und Rosenberg SA, 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. *J Immunol*, 142(10):3714-25.
- Trapani JA, Sutton VR und Smyth MJ, 1999. CTL granules: evolution of vesicles essential for combating virus infections. *Immunol Today*, 20:352-356.
- Trubiani O, Bosco D und Di Primio R, 1994. Interferon-gamma (IFN-gamma) induces programmed cell death in differentiated human leukemic B cell lines. *Exp Cell Res*. 215:23-27.



- Untch M, Ditsch N und Hermelink K, 2003. Immunotherapy: new options in breast cancer treatment. *Expert Rev Anticancer Ther*, 3:403-408.
- Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet M J, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini J-C und Romero P, 2000. Naturally occurring human Lymphocyte antigen-A2 restricted CD8<sup>+</sup> T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. *Cancer Res*, 60:4499-4506.
- Valmori D, Pittet M J, Vonarbourg C, Rimoldi D, Liénard D, Speiser D, Dunbar R, Cerundulo V, Cerottini und Romero P, 1999. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A 2.1-associated Tyrosinase peptide 368-376. *Cancer Res*, 59:4050-4055
- Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemisen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Liénard D und Keilholz U, 2002. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. *Cancer Res*, 62:1743-1750.
- Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R und Boon T, 1989. Presence on a human melanoma of multiple antigens recognized by autologous CTL. *Int J Cancer*, 44:634-640.
- Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A und Boon T, 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science*, 254:1643-1647.
- Vivier E, Morin P, O'Brien C, Druker B, Schlossman SF und Anderson P, 1991. Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. *J Immunol*, 146:206-210.

- Von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A and Simon JC 1999. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. *Cancer Res*, 59:1287-1294.
- Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Goshen SG, Gee C, Jeffery GG, Sian S und Lee PP, 2003. Granulocyte-macrophage-colony-stimulation factor added to a multipeptide vaccine for resected Stage II melanoma. *Cancer*, 97:186-200.
- Whiteside T L, Zhao Y, Tsukishiro T, Elder E M, Gooding W und Baar J, 2003. Enzyme-linked Immunospot, cytokine flow cytometry, and tetramers in the detection of T-Cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. *Clin Cancer Res*, 9:641-649.
- Whiteside TL und Rabinowich H, 1998. The role of Fas/FasL in immunosuppression induced by human tumors. *Cancer Immunol Immunother*, 46:175-184.
- Whittington R und Faulds D, 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. *Drugs*, 46:446-514.
- Wölfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, Boon T und Meyer Zum Büschenfelde KH, 1993. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). *Int J Cancer*, 55:237-44.
- Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH und Boon T, 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. *Eur J Immunol*. 24:759-764.
- Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M und Rosenberg SA, 1996. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. *Int J Cancer*, 65:413-421.

- Yee C, Savage PA, Lee PP, Davis MM und Greenberg PD, 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. *J Immunol*, 162:2227-2234.
- Yee C, Thompson J A, Byrd D, Riddell SR, Roche P, Celis E und Greenberg PD, 2002. Adoptive T cell therapy using antigen-specific CD8<sup>+</sup> T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. *Proc Natl Acad Sci USA*, 99:16168-16173.
- Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR und Greenberg PD, 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. *J Exp Med*, 192:1637-1644.
- Zinkernagel RM und Doherty PC, 1974. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. *Nature*, 251:547-548.